MCL1 and hematologic disorder: AMG176 and AMG397: AMG176 (tapotoclax) is a potent, specific, and orally available MCL1 inhibitor developed by Amgen (www.amgen.com).373 Following an initial safety study (NCT02675452), AMG176 was investigated in combination with venetoclax in patients with R/R hematologic malignancies (NCT03797261), which has been suspended, and in combination with azacitidine in patients with MDS/CML (NCT05209152), which has been completed.